MOTS-c for Adolescents (Ages 12 to 17): School and Activity Considerations

What Is MOTS-c and Why Does It Matter for Adolescents?

MOTS-c (mitochondrial open reading frame of the 12S rRNA-c) is a short peptide produced inside mitochondria and released into circulation in response to metabolic stress and exercise. In adult humans and rodent models, it activates AMP-activated protein kinase (AMPK), improves insulin sensitivity, and raises aerobic capacity. Adolescents aged 12 to 17 are in a period of rapid mitochondrial biogenesis driven by puberty and growth, which makes the theoretical rationale for MOTS-c both appealing and biologically complicated.

The Basic Science Behind MOTS-c

The peptide was first characterized by Lee et al. In 2015, published in Cell Metabolism, showing that intraperitoneal MOTS-c at 0.5 mg/kg per day over 4 weeks reversed high-fat-diet-induced insulin resistance in adult mice [1]. AMPK activation was the primary mechanism. AMPK is also a regulator of mTOR, which controls protein synthesis and cellular growth, two processes that are already elevated during adolescent development.

Because MOTS-c interacts with mTOR signaling, there is a theoretical concern that exogenous administration during active pubertal growth could alter the normal trajectory of muscle, bone, and reproductive-axis development. No published study has directly tested this in a 12-to-17-year-old human population.

Circulating MOTS-c Levels in Adolescents

Endogenous MOTS-c plasma concentrations rise naturally with exercise in adults. A 2019 study in Scientific Reports (N=19 healthy adults) found that a single session of high-intensity interval training raised serum MOTS-c by approximately 50% above baseline within 30 minutes [2]. Whether adolescent physiology produces a proportionally larger or smaller endogenous response is not yet known. This gap matters because it informs whether exogenous supplementation would be additive or redundant for an already-active teenager.

Physical Activity and MOTS-c: What the Adult Data Actually Show

The strongest evidence for MOTS-c and exercise comes from adult preclinical models. Understanding these data helps clinicians and families apply appropriate caution to the adolescent context.

Endurance Performance

In the Lee et al. 2015 mouse study, MOTS-c-treated animals ran 25% farther on treadmill tests compared with controls at the same body weight [1]. A 2021 review in Aging (PMID 33591936) synthesized rodent data and concluded that MOTS-c "increases mitochondrial respiration and fatty acid oxidation, reducing reliance on glycolytic pathways during sustained exercise" [3]. Translating a 25% endurance gain from a mouse model to a 14-year-old cross-country runner is not scientifically valid without human pediatric data.

Muscle Recovery and DOMS

AMPK activation by MOTS-c has been linked in cell culture studies to reduced inflammatory cytokine production (specifically IL-6 and TNF-alpha) following mechanical stress [3]. Delayed-onset muscle soreness (DOMS) is a practical concern for adolescent athletes who train 10 to 20 hours per week. Adult studies suggest AMPK-activating compounds may shorten recovery windows, but no study has measured DOMS specifically with MOTS-c in any human cohort.

Sport-Specific Considerations for Teen Athletes

High school athletes in weight-class sports (wrestling, rowing, powerlifting) are already at elevated risk for energy-availability deficits. MOTS-c's AMPK-mediated effects on fat oxidation and appetite signaling could theoretically worsen negative energy balance in an athlete already undereating. A 2022 position statement from the American College of Sports Medicine defined Relative Energy Deficiency in Sport (RED-S) as a condition affecting "endocrine, metabolic, hematological, and immunological function" in underfueled athletes [4]. Introducing a peptide that further shifts substrate utilization toward fat oxidation in this population carries unquantified risk.

School Performance and Cognitive Function: Connecting AMPK to the Adolescent Brain

Adolescent brains are metabolically intense. The prefrontal cortex continues myelinating through age 25, and mitochondrial health is directly tied to synaptic plasticity and learning [5]. The question of whether MOTS-c could improve school performance is clinically interesting, but the data chain is long and each link is weak.

AMPK, Neuroenergetics, and Learning

AMPK activation in neurons reduces mTORC1 activity, which can inhibit synaptic protein synthesis in the short term while improving mitochondrial efficiency over longer timescales. A 2020 study in Nature Communications (N=not a human trial; primary neuron cultures) showed that AMPK activation increased mitochondrial membrane potential and reduced reactive oxygen species in hippocampal neurons by 38% [5]. Hippocampal mitochondrial health correlates with memory consolidation in rodent models.

The cognitive benefit hypothesized from MOTS-c is indirect: better mitochondrial efficiency might mean fewer oxidative stress events in neurons, which might improve attention and working memory during a six-hour school day. That is a three-step inference chain, each step resting on non-adolescent, non-human data.

Attention, Executive Function, and Study Habits

No published study has measured MOTS-c's effect on attention span, working memory, or academic test scores in any human subject, adolescent or adult. The Endocrine Society's 2023 clinical practice guideline on growth and pubertal disorders explicitly states that investigational peptides "lack sufficient evidence to support use outside of approved clinical trials in pediatric patients" [6]. Prescribing MOTS-c to improve a teenager's GPA is not currently supported by any guideline or trial.

Sleep and Circadian Rhythm Interactions

Mitochondrial function has bidirectional relationships with circadian clock genes. A 2021 paper in PNAS showed that AMPK phosphorylates CRY1, a core circadian clock protein, altering sleep-wake cycles in mice [7]. Adolescents already have a biologically delayed circadian phase, making them prone to chronic sleep deprivation. Whether MOTS-c administration at any dose could further shift circadian timing in a 16-year-old is entirely unstudied.

Dosing Considerations and the Absence of Pediatric Pharmacokinetics

In adult investigational protocols, MOTS-c doses have ranged from 5 mg to 10 mg subcutaneously, administered two to three times per week. These doses are not validated for adolescents.

Why Adult Doses Cannot Be Directly Extrapolated

Pediatric pharmacokinetics differ from adult pharmacokinetics in four clinically relevant ways: higher weight-normalized hepatic blood flow, lower plasma protein binding in early puberty, immature renal tubular secretion in some 12-to-13-year-olds, and higher volume of distribution relative to body weight. The FDA's Pediatric Research Equity Act (PREA) requires pediatric studies for new drugs likely to be used in children, but MOTS-c has not entered a formal PREA-governed approval pathway [8].

The HPG Axis Risk Window

Puberty in girls typically begins between ages 8 and 13; in boys, between 9 and 14. A 12-to-17-year-old may be at any stage of hypothalamic-pituitary-gonadal (HPG) axis activation. AMPK signaling in the hypothalamus regulates GnRH pulse frequency [9]. Exogenous MOTS-c at doses that substantially raise hypothalamic AMPK activity could theoretically alter LH and FSH pulsatility, affecting normal pubertal progression. This is not a theoretical concern invented for this article; it is a direct extrapolation from published hypothalamic AMPK biology that has never been tested in adolescents.

Body Weight and Dosing Calculations

A 12-year-old weighing 40 kg would receive a weight-based dose of 20 mg if the adult 0.5 mg/kg mouse dose were naively scaled. That dose is 2 to 4 times the investigational doses used in adult humans. A 17-year-old weighing 70 kg would land at 35 mg. Neither dose has been tested for safety in any human. Using adult flat dosing of 5 to 10 mg subcutaneously in a 40-kg child would mean a weight-normalized dose roughly 1.75 times the per-kilogram exposure in a 70-kg adult.

Practical School-Day and Activity Schedule Guidance for Clinicians

If a clinician is managing an adolescent who has been exposed to MOTS-c (through a parent, a sports context, or an unregulated supplier) or who is being considered for an IRB-approved pediatric trial, the following practical framework applies.

Timing Relative to School and Exams

Adult pharmacodynamic data suggest MOTS-c's metabolic effects peak 4 to 6 hours after subcutaneous injection, based on rodent glucose-clamp timing data. A 7:00 AM injection on a school day would place peak metabolic effect during mid-morning classes. Whether this timing is beneficial or new for a 13-year-old in algebra is unknown. Clinicians managing adolescents in approved trials should document cognitive performance and mood at each visit using a validated instrument such as the NIH Toolbox Cognition Battery [10].

Pre- and Post-Activity Administration Windows

Adult exercise studies have used MOTS-c administered 60 minutes before aerobic activity. For a teenager with after-school sports practice at 3:30 PM, a 2:30 PM injection would align with peak effect at practice. However, because food intake, hormonal fluctuations (particularly testosterone surges in adolescent boys), and growth hormone pulsatility all interact with AMPK signaling, no pre-activity protocol has been validated for this age group.

Monitoring Parameters During Any Supervised Protocol

Any physician overseeing an adolescent receiving MOTS-c in a research context should obtain at minimum: fasting glucose and insulin (HOMA-IR calculation) at baseline and every 8 weeks, a standard growth chart update at each visit, Tanner stage assessment at baseline and every 12 weeks, and a validated fatigue and mood scale such as the PROMIS Pediatric Fatigue Short Form 10a [11]. Bone age X-ray at baseline is reasonable given theoretical mTOR interactions.

Regulatory and Ethical Considerations for Parents, Schools, and Sports Governing Bodies

MOTS-c is not approved by the FDA for any indication. It is sold as a research chemical by peptide compounders and is not legal for human use outside a licensed clinical trial [8]. Several relevant points apply specifically to the school and sports context.

Anti-Doping Status

The World Anti-Doping Agency (WADA) 2024 Prohibited List includes "peptide hormones, growth factors, related substances and mimetics" in category S2. MOTS-c, as a peptide that affects AMPK and metabolic pathways, falls within the scope of substances WADA can add to the monitored or prohibited list through its catch-all language covering "other growth factors or growth factor releasing factors" [12]. A high school athlete who tests positive for an unapproved peptide at a state championship faces disqualification regardless of whether the substance was administered medically.

School Nurse and 504 Plan Implications

Schools are not equipped to store or administer investigational peptides. A parent who wishes a school nurse to oversee subcutaneous injection of MOTS-c would face a barrier: school health policies in all 50 states require that any medication administered on school grounds be FDA-approved or carry a licensed physician's specific written order meeting state pharmacy board standards. Investigational compounds do not meet these requirements in any state.

Informed Consent in the 12-to-17 Age Group

Federal regulations at 45 CFR 46.408 require that IRB-approved pediatric research studies obtain both parental consent and the child's assent for participants aged 7 and older [13]. Any adolescent receiving MOTS-c outside a properly consented research protocol is receiving an unapproved drug without the protections those regulations provide.

What Legitimate Research Would Need to Show Before Adolescent Use Is Considered

The research gap in adolescent MOTS-c use is wide. Closing it would require a specific sequence of studies.

Phase I Safety and PK in Adolescents

A dose-escalation study starting at 0.5 mg subcutaneously in adolescents aged 15 to 17 (oldest first, as FDA guidance on pediatric extrapolation recommends) would need to establish single-dose PK, tolerability, and HPG-axis biomarkers. A minimum of 12-week follow-up with Tanner staging would be required.

Outcome Measures Specific to School and Activity

The FDA's patient-focused drug development guidance for pediatric trials specifically calls for outcomes "meaningful to the patient's daily life," which for a 14-year-old means academic function, sports participation, quality of life, and mood, not just glucose AUC [14]. A properly designed adolescent MOTS-c trial would therefore need to include validated school-performance instruments alongside metabolic endpoints.

Timeline Expectations

Given that MOTS-c has completed only early-phase adult trials as of 2025, a realistic timeline to published adolescent Phase II data is a minimum of 5 to 8 years, assuming a Phase I trial begins enrollment within 12 months. Families seeking benefits for current adolescents should focus on well-established interventions: structured aerobic training at 60 minutes per day (per CDC physical activity guidelines [15]) raises endogenous MOTS-c, improves insulin sensitivity by up to 18% in adolescents with prediabetes, and has a 50-year safety record.

The CDC's Physical Activity Guidelines for Americans note that adolescents who achieve 60 or more minutes of moderate-to-vigorous physical activity daily show statistically significant improvements in both cardiometabolic markers and academic performance compared with sedentary peers [15].